BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget 2017;8:44073-81. [PMID: 28454122 DOI: 10.18632/oncotarget.17237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Herbst B, Zheng L. Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology & Hepatology 2019;4:805-10. [DOI: 10.1016/s2468-1253(19)30175-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Crowley F, Park W, O'Reilly EM. Targeting DNA damage repair pathways in pancreas cancer. Cancer Metastasis Rev 2021. [PMID: 34403012 DOI: 10.1007/s10555-021-09983-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281. [PMID: 30574212 DOI: 10.1177/1758835918816281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
4 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
5 Verdaguer H, Arroyo A, Macarulla T. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. Targ Oncol 2018;13:691-704. [DOI: 10.1007/s11523-018-0609-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kang BW, Chau I. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opin Investig Drugs 2021;:1-19. [PMID: 34727804 DOI: 10.1080/13543784.2021.1995354] [Reference Citation Analysis]
7 Sun J, Russell CC, Scarlett CJ, McCluskey A. Small molecule inhibitors in pancreatic cancer. RSC Med Chem 2020;11:164-83. [PMID: 33479626 DOI: 10.1039/c9md00447e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
8 Tsang ES, Wong HL, Wang Y, Renouf DJ, Cheung WY, Lim HJ, Gill S, Loree JM, Kennecke HF. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. Am J Clin Oncol 2019;42:196-201. [PMID: 30499841 DOI: 10.1097/COC.0000000000000500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
9 Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108-123. [PMID: 31705130 DOI: 10.1038/s41571-019-0281-6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 26.3] [Reference Citation Analysis]
10 Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation. Medicine (Baltimore) 2019;98:e17443. [PMID: 31577767 DOI: 10.1097/MD.0000000000017443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Cancer Treat Rev 2021;100:102262. [PMID: 34418781 DOI: 10.1016/j.ctrv.2021.102262] [Reference Citation Analysis]
12 Noë M, Hong SM, Wood LD, Thompson ED, Roberts NJ, Goggins MG, Klein AP, Eshleman JR, Kern SE, Hruban RH. Pancreatic cancer pathology viewed in the light of evolution. Cancer Metastasis Rev 2021. [PMID: 33555482 DOI: 10.1007/s10555-020-09953-z] [Reference Citation Analysis]
13 Li M, Mou Y, Hou S, Cao D, Li A. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report. Medicine (Baltimore) 2018;97:e13113. [PMID: 30407325 DOI: 10.1097/MD.0000000000013113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2018;226:630-637.e1. [PMID: 29309945 DOI: 10.1016/j.jamcollsurg.2017.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
15 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021; 27(35): 5851-5889 [PMID: 34629806 DOI: 10.3748/wjg.v27.i35.5851] [Reference Citation Analysis]
16 Chiaravalli M, Reni M, O'reilly EM. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews 2017;60:32-43. [DOI: 10.1016/j.ctrv.2017.08.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
17 Hsiao YW, Lu TP. Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers. J Pers Med 2021;11:1287. [PMID: 34945758 DOI: 10.3390/jpm11121287] [Reference Citation Analysis]
18 Thompson ED, Roberts NJ, Wood LD, Eshleman JR, Goggins MG, Kern SE, Klein AP, Hruban RH. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol 2020;33:2544-63. [PMID: 32704031 DOI: 10.1038/s41379-020-0629-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Halder R, Shroff RT. What is the role of PARP inhibitors in pancreatic cancer? Expert Rev Anticancer Ther 2020;20:913-8. [PMID: 32865047 DOI: 10.1080/14737140.2020.1816174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treat Rev 2019;75:27-38. [PMID: 30927677 DOI: 10.1016/j.ctrv.2019.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
21 Das S, Cardin D. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. Curr Treat Options Oncol. 2020;21:62. [PMID: 32601814 DOI: 10.1007/s11864-020-00763-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Jeong KY, Park MH. The Significance of Targeting Poly (ADP-Ribose) Polymerase-1 in Pancreatic Cancer for Providing a New Therapeutic Paradigm. Int J Mol Sci 2021;22:3509. [PMID: 33805293 DOI: 10.3390/ijms22073509] [Reference Citation Analysis]
23 Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, Takaori K, Matsumoto S, Miyake H, Okuno Y, Muto M. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget 2018;9:19817-25. [PMID: 29731985 DOI: 10.18632/oncotarget.24865] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
24 Skelding KA, Lincz LF. PARP Inhibitors and Haematological Malignancies-Friend or Foe? Cancers (Basel) 2021;13:5328. [PMID: 34771492 DOI: 10.3390/cancers13215328] [Reference Citation Analysis]
25 Di Federico A, Tateo V, Parisi C, Formica F, Carloni R, Frega G, Rizzo A, Ricci D, Di Marco M, Palloni A, Brandi G. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals (Basel) 2021;14:677. [PMID: 34358103 DOI: 10.3390/ph14070677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials. Cancer Manag Res 2019;11:3061-78. [PMID: 31114351 DOI: 10.2147/CMAR.S191107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci 2020;111:3111-21. [PMID: 32639661 DOI: 10.1111/cas.14565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
28 Bisht S, Feldmann G. Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. Oncol Res Treat 2018;41:596-602. [PMID: 30269126 DOI: 10.1159/000493437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
29 Alkassis S, Yazdanpanah O, Philip PA. BRCA mutations in pancreatic cancer and progress in their targeting. Expert Opin Ther Targets 2021;25:547-57. [PMID: 34289788 DOI: 10.1080/14728222.2021.1957462] [Reference Citation Analysis]
30 Hammel P, Zhang C, Matile J, Colle E, Hadj-Naceur I, Gagaille MP, Bouattour M, Cros J, de Mestier L, Lamuraglia M. PARP inhibition in treatment of pancreatic cancer. Expert Rev Anticancer Ther 2020;20:939-45. [PMID: 32936674 DOI: 10.1080/14737140.2020.1820330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers (Basel) 2021;13:799. [PMID: 33672917 DOI: 10.3390/cancers13040799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Pook H, Pauklin S. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4834. [PMID: 34638318 DOI: 10.3390/cancers13194834] [Reference Citation Analysis]
33 Alhusaini A, Cannon A, Maher SG, Reynolds JV, Lynam-Lennon N. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers. Biomedicines 2021;9:1024. [PMID: 34440228 DOI: 10.3390/biomedicines9081024] [Reference Citation Analysis]
34 Bijou I, Wang J. Evolving trends in pancreatic cancer therapeutic development. Ann Pancreat Cancer 2019;2:17. [PMID: 33089149 DOI: 10.21037/apc.2019.09.01] [Reference Citation Analysis]
35 Suenaga M, Yu J, Shindo K, Tamura K, Almario JA, Zaykoski C, Witmer PD, Fesharakizadeh S, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clin Cancer Res. 2018;24:2963-2974. [PMID: 29301828 DOI: 10.1158/1078-0432.ccr-17-2463] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
36 Vogl UM, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B, Kafka A, Winkler T, Öhler L. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? BMC Cancer 2019;19:28. [PMID: 30621630 DOI: 10.1186/s12885-018-5240-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
37 Balboni A, Govoni M, Rossi V, Roberti M, Cavalli A, Di Stefano G, Manerba M. Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment. Biochim Biophys Acta Gen Subj 2021;1865:129760. [PMID: 33035602 DOI: 10.1016/j.bbagen.2020.129760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Desai D, Khandwala P, Parsi M, Potdar R. PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. Med Oncol 2021;38:61. [PMID: 33891252 DOI: 10.1007/s12032-021-01507-9] [Reference Citation Analysis]
39 Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, Clay MR, Bahrami A, McCarville MB, Kaste SC, Santana VM, Helmig S, Gartrell J, Shelat A, Brennan RC, Hawkins D, Godwin K, Bishop MW, Furman WL, Stewart E. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer 2020;137:204-13. [PMID: 32795876 DOI: 10.1016/j.ejca.2020.06.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
40 Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 2021;70:606-17. [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
41 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]